Cognitive behavioral treatment of residual symptoms in primary major depressive disorder

1994 ◽  
Vol 151 (9) ◽  
pp. 1295-1299 ◽  
2012 ◽  
Vol 15 (3) ◽  
pp. 1388-1399 ◽  
Author(s):  
Francisco José Estupiñá Puig ◽  
Francisco Javier Labrador Encinas

Major Depressive Disorder (MDD) is the most prevalent mental disorder in our environment, and one of the main causes of disability. While several empirically supported treatments (ESTs) for MDD exist, some doubts have been cast on the applicability—in time, components, and effectiveness—of these ESTs in routine clinical practice. A few attempts have been made to contrast the effectiveness of ESTs, but usually the precise components of the treatment developed are not considered in detail. The purpose of this study is to analyze the components of an EST-based treatment on a sample of 69 MDD cases from a University Psychology Clinic, and to benchmark them against the results of published efficacy studies on ESTs (behavioral activation, cognitive therapy, interpersonal therapy). Results show that treatments delivered at this clinical facility are similar in components, length, and effectiveness (in effect size, completers and improved ratio) to the benchmarked studies. Cognitive restructuring is the most frequent component of the delivered treatments. Therapy results show a 3.12 effect size, and a 55.1% improved ratio over initial sample, an 80% of completers. Results and limitations of the current study, especially those related to sample and center characteristics, are discussed.


SLEEP ◽  
2008 ◽  
Vol 31 (4) ◽  
pp. 489-495 ◽  
Author(s):  
Rachel Manber ◽  
Jack D. Edinger ◽  
Jenna L. Gress ◽  
Melanie G. San Pedro-Salcedo ◽  
Tracy F. Kuo ◽  
...  

2018 ◽  
Vol 49 (11) ◽  
pp. 1869-1878 ◽  
Author(s):  
Boadie W. Dunlop ◽  
Philip E. Polychroniou ◽  
Jeffrey J. Rakofsky ◽  
Charles B. Nemeroff ◽  
W. Edward Craighead ◽  
...  

AbstractBackgroundPersisting symptoms after treatment for major depressive disorder (MDD) contribute to ongoing impairment and relapse risk. Whether cognitive behavior therapy (CBT) or antidepressant medications result in different profiles of residual symptoms after treatment is largely unknown.MethodsThree hundred fifteen adults with MDD randomized to treatment with either CBT or antidepressant medication in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study were analyzed for the frequency of residual symptoms using the Montgomery Asberg Depression Rating Scale (MADRS) item scores at the end of the 12-week treatment period. Separate comparisons were made for treatment responders and non-responders.ResultsAmong treatment completers (n= 250) who responded to CBT or antidepressant medication, there were no significant differences in the persistence of residual MADRS symptoms. However, non-responders treated with medication were significantly less likely to endorse suicidal ideation (SI) at week 12 compared with those treated with CBT (non-responders to medication: 0/54, 0%, non-responders to CBT: 8/30, 26.7%;p= .001). Among patients who terminated the trial early (n= 65), residual MADRS item scores did not significantly differ between the CBT- and medication-treated groups.ConclusionsDepressed adults who respond to CBT or antidepressant medication have similar residual symptom profiles. Antidepressant medications reduce SI, even among patients for whom the medication provides little overall benefit.


2018 ◽  
Vol 262 ◽  
pp. 469-476 ◽  
Author(s):  
Gianluca Serafini ◽  
Jacopo Nebbia ◽  
Nicolò Cipriani ◽  
Claudia Conigliaro ◽  
Denise Erbuto ◽  
...  

2007 ◽  
Vol 34 (1) ◽  
pp. 13-23 ◽  
Author(s):  
Timothy J. Petersen ◽  
Joel A. Pava ◽  
Jacqueline Buchin ◽  
John D. Matthews ◽  
George I. Papakostas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document